Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CRHBP | P24387 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MARS1 | P56192 | 8/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | ADH5 | P11766 | 1/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23484575 | 0.89 | SRD5A2 (0.73) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL6253145 | 0.89 | SRD5A2 (0.72) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| Hydrochloric Acid SCHEMBL9812960 | 0.87 | SRD5A2 (0.70) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL5705016 | 0.86 | SRD5A2 (0.69) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL4300785 | 0.85 | SRD5A2 (0.68) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL8779218 | 0.85 | SRD5A2 (0.68) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL29788156 | 0.85 | SRD5A2 (0.68) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL2050887 | 0.85 | SRD5A2 (0.68) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL30837198 | 0.84 | SRD5A2 (0.66) | SRD5A2KDM4ENPC1CRHBPRAB9A | |
| SCHEMBL10717595 | 0.84 | SRD5A2 (0.66) | SRD5A2RXRARXRBADH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | claimed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | claimed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| CN-114773249-B | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| WO-2004024702-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004006924-A1 | ARYL PIPERIDINE DERIVATIVES AND USE THEREOF TO REDUCE ELEVATED LEVELS OF LDL-CHOLESTEROL | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006923-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | GLAXO GROUP LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| EP-1140072-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1140072-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001064213-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000040239-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SRD5A2 1080/4885KDM4E 4211/4885NPC1 737/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | SRD5A2 1328/4885KDM4E 492/4885NPC1 2495/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | SRD5A2 3298/4885KDM4E 916/4885NPC1 4357/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SRD5A2 1080/4885KDM4E 4211/4885NPC1 737/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SRD5A2 1080/4885KDM4E 4211/4885NPC1 737/4885 |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | SRD5A2 1228/4885KDM4E 2042/4885NPC1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.